Serbia’s Bold Move to Shield Newborns from a Devastating Condition
Dr. Miloš Brkušanin and colleagues describe how scientists, doctors, patient groups and policymakers established nationwide genetic newborn screening for spinal muscular atrophy in Serbia, enabling early treatment.
Read the original paper
Spinal muscular atrophy poses a significant concern for healthcare providers. This rare genetic condition primarily affects children, weakening muscles and impairing movement and other essential functions. Without early diagnosis and treatment, it is fatal in most cases. Motivated by its devastating impact on infants and their families, Serbia has made a determined effort to establish a nationwide program for newborn screening.
This inspiring story of teamwork and innovation was made possible by Serbian scientists, led by Dr. Miloš Brkušanin, alongside doctors, patient advocates, pharmaceutical companies, and policymakers. Together, they tackled the challenges of addressing SMA, ensuring every newborn in Serbia is tested for this life-altering condition. Their work is detailed in a study published in the International Journal of Neonatal Screening, a respected platform for medical research.
Using specialized techniques to analyze DNA, Serbia’s program identifies affected babies shortly after birth. Early diagnosis enables timely treatment, vastly improving outcomes and giving children the best chance for healthy development. “Our mission is simple but powerful: detect spinal muscular atrophy as early as possible to enable successful treatment,” said Dr. Brkušanin.
The research emphasizes how government support and partnerships ensured that testing is accessible to all newborns, regardless of location or financial circumstances. “Our top priority was ensuring that every child could get early testing and treatment,” Dr. Brkušanin added. Detailed planning, expert knowledge, and collaboration among scientists, doctors, pharmaceutical companies, and patient organizations transformed Serbia’s program into a model for other countries. Several babies diagnosed through the system have already received life-changing treatments, showing promising progress.
“This achievement marks the dawn of a new era in neonatal screening, leveraging genetic methods to bring hope to families affected by SMA and other treatable rare diseases,” said Professor Dušanka Savić-Pavićević. Experts highlight the importance of global collaboration and shared resources to address health challenges together. Serbia’s success demonstrates how science, combined with a commitment to public health, can create extraordinary change.
By establishing this program, Serbia has not only given affected families a lifeline but also provided a powerful example of what can be achieved through pragmatic ideas, determination and cooperation.
About the researchers
Journal reference
Brkušanin M, Garai N, Karanović J, et al. “Our Journey from Individual Efforts to Nationwide Support: Implementing Newborn Screening for Spinal Muscular Atrophy in Serbia.” Int J Neonatal Screen. 2024;10(3):57. DOI: https://doi.org/10.3390/ijns10030057





